Thrombocytopenia due to increased platelet destruction is seen in-
**Question:** Thrombocytopenia due to increased platelet destruction is seen in-
A. Splenomegaly
B. Immune thrombocytopenic purpura (ITP)
C. Liver cirrhosis
D. Chronic myeloproliferative disorders
**Core Concept:**
Thrombocytopenia is a condition characterized by a decrease in platelet count in the blood. Platelets, also known as thrombocytes, are small cell fragments produced in the bone marrow that play a crucial role in blood clotting. Increased platelet destruction refers to a situation where more platelets are removed from the circulation than are produced, leading to a decrease in platelet count.
**Why the Correct Answer is Right:**
Thrombocytopenia due to increased platelet destruction is primarily seen in the context of immune thrombocytopenic purpura (ITP), a disorder characterized by the production of autoantibodies against platelet surface antigens. These autoantibodies bind to platelets, causing them to be rapidly cleared from the circulation by the reticuloendothelial system (RES), particularly the spleen. Consequently, the platelet count decreases, leading to symptoms like easy bruising, petechiae, and mucosal bleeding.
**Why Each Wrong Option is Incorrect:**
1. Splenomegaly (enlarged spleen) can cause increased platelet destruction, but the correct answer is ITP as it is a specific condition causing increased platelet destruction through autoimmune mechanisms.
2. Liver cirrhosis is associated with platelet sequestration (storage of platelets in the liver), not increased platelet destruction.
3. Chronic myeloproliferative disorders (e.g., chronic myeloid leukemia) are characterized by increased platelet production, not destruction.
**Clinical Pearl:**
In clinical practice, recognizing the cause of thrombocytopenia is essential for appropriate management and prognosis. ITP requires specific treatment strategies, whereas splenomegaly and liver cirrhosis may be managed differently. Understanding the underlying mechanism helps in choosing the appropriate therapeutic approach and monitoring patient outcomes.